Patent · US Active

MMP13 binding immunoglobulins

US12129308B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignees

Merck Patent GmbH · DE
Ablynx N.V. · BE

Inventors

Francis Descamps · Roeselare, BE
Gerald Beste · Evergem, BE
Guy Hermans · Merelbeke, BE
Hans Guehring · Eltville am Rhein, DE
Lars Toleikis · Kleinniedesheim, DE
Christoph H. Ladel · Darmstadt, DE

Key dates

Filing date	Jun 4, 2018
Grant date	Oct 29, 2024
Priority date	—
Expiry date	Jun 4, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to immunoglobulins that specifically bind MMP13 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit an activity of MMP13 and preferably are also stable.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.